Heart Disease News and Research

Latest Heart Disease News and Research

New study finds propofol poses low risk for children undergoing research-driven imaging studies

A new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

10 Jun 2010

Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary Phase 2 data describing the methodology used to define an imaging protocol for a one-day rest-stress myocardial perfusion imaging test using its novel investigational PET imaging agent flurpiridaz F 18 injection (formerly known as BMS747158).

10 Jun 2010

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Genzyme Corporation and Carl C. Icahn and certain of his affiliated private investment funds announced today an agreement to settle their proxy contest.

10 Jun 2010

DermaGenoma releases CelluliteDX Genetic Test for women

As summer swimsuit season heats up, women around the world will inspect their looks in the mirror. A majority of them will see cellulite - at some point - but a new genetic test may be able to help them avoid cellulite before anyone notices.

10 Jun 2010

Emergency hospital admissions for heart attacks drop by 2.4% following smoke-free legislation

The introduction of smoke-free legislation in England was followed by a 2.4 per cent drop in the number of emergency hospital admissions for heart attacks, new research shows.

10 Jun 2010

Sialidase improves nerve regrowth, motor recovery and nervous system function: Researchers

Once damaged, nerves in the spinal cord normally cannot grow back and the only drug approved for treating these injuries does not enable nerve regrowth. Publishing online this week in the Early Edition of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine show that treating injured rat spinal cords with an enzyme, sialidase, improves nerve regrowth, motor recovery and nervous system function.

10 Jun 2010

New study affirms relationship between depression and abdominal obesity

A new study at the University of Alabama at Birmingham confirms the relationship between depression and abdominal obesity, which has been linked to an increased risk for cancer and cardiovascular disease.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Microscopic polymer fibers for rebuilding human tissue, speeding healing process

Queen's University Brian Amsden is hoping that in about 10 years a tendon, spinal cord or heart valve will be able to regenerate itself after an injury or disease. The chemical engineering professor, along with scientists from the University of Western Ontario and University of Toronto, is currently trying to develop microscopic polymer fibers to help rebuild human tissue and speed the healing process.

10 Jun 2010

Synteract joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Synteract has joined Medidata's ASPire to Win® channel partner program. A full-service contract research organization (CRO) with an increasing global presence and extensive experience working with emerging biotech, pharmaceutical and medical device sponsors, Synteract will offer services around Medidata Rave®, the market-leading electronic data capture (EDC) and clinical data management (CDM) solution.

9 Jun 2010

Caritas Christi Health Care implements MedAptus' Intelligent Charge Capture suite

MedAptus(R), the market leader for charge capture technologies, today announced that Caritas Christi Health Care, also based in Boston, has implemented the company's Intelligent Charge Capture suite for revenue and compliance enhancement initiatives. The organization selected MedAptus' Practice Plus Edition on BlackBerry smartphone devices and web-enabled workstations for the capture of physician inpatient charges. In addition, Caritas Christi is rolling out the MedAptus Facility Edition for the capture of outpatient clinic charges, starting in the area of cardiology.

9 Jun 2010

University Health Systems of Eastern Carolina licensed A.D.A.M. health tools for their hospital websites

A.D.A.M., Inc., a leading provider of health information and benefits technology solutions announced today that University Health Systems of Eastern Carolina has licensed the A.D.A.M. Multimedia Encyclopedia, Heart Center, and other A.D.A.M. health tools for eight of their hospital websites. The A.D.A.M. health information allows the system to provide more robust online health and wellness information to the counties served by the hospital system, and empowers people within those communities to lead healthier lives.

9 Jun 2010

New AAN guideline provides step-by-step process for determining brain death in adults

In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2010

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

A group of top international scientists including geneticists from the Royal College of Surgeons in Ireland has made a breakthrough in understanding human adaptation to high altitude environments.

9 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

LUMEDX certified as official ACC-NCDR ICD Registry 2.0 software vendor

The American College of Cardiology has certified LUMEDX Corporation--the industry leader in integrated cardiovascular information systems and the number one provider of ACC software--as an official ACC-NCDR ICD Registry 2.0 software vendor. LUMEDX's Export to ICD Registry solution is the latest in a suite of software applications developed to address the growing need for impeccable, accessible cardiovascular data, streamlined clinical workflows and superior data management.

9 Jun 2010

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

The "gold standard" diabetes test, Hemoglobin A1c (A1C), explains much less about the risk of cardiovascular complications in patients with diabetes than originally thought, according to an article in the June 9 issue of the Journal of the American Medical Association (JAMA). The article entitled, "Beyond HbA1c: Need for Additional Markers of Risk for Diabetic Microvascular Complications," was co-authored by Irl Hirsch, M.D., of the University of Washington Medical School (Seattle, WA) and Michael Brownlee, M.D., of the Albert Einstein College of Medicine.

9 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Select patients with blunt aortic injury can be safely managed non-operatively with beta-blockade to lower the heart rate and blood pressure, according to a new study from the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.

9 Jun 2010

Clinical guidelines for UC emergency medicine physicians

Though guidelines for best treatment practices are common, they are only partially effective without standardized, routine exposure to them in clinical practice, according to a study conducted by University of Cincinnati emergency medicine researchers.

9 Jun 2010

Heart Disease News and Research

Latest Heart Disease News and Research

New study finds propofol poses low risk for children undergoing research-driven imaging studies

Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

DermaGenoma releases CelluliteDX Genetic Test for women

Emergency hospital admissions for heart attacks drop by 2.4% following smoke-free legislation

Sialidase improves nerve regrowth, motor recovery and nervous system function: Researchers

New study affirms relationship between depression and abdominal obesity

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Microscopic polymer fibers for rebuilding human tissue, speeding healing process

Synteract joins Medidata's ASPire to Win channel partner program

Caritas Christi Health Care implements MedAptus' Intelligent Charge Capture suite

University Health Systems of Eastern Carolina licensed A.D.A.M. health tools for their hospital websites

New AAN guideline provides step-by-step process for determining brain death in adults

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

LUMEDX certified as official ACC-NCDR ICD Registry 2.0 software vendor

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Clinical guidelines for UC emergency medicine physicians

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Heart Disease News and Research

Latest Heart Disease News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in